What AbbVie's 8-K filings say: 8 filings, latest Sep 3, 2026

AbbVie filed its latest 8-K with the SEC on Sep 3, 2026. It discusses acquisition completed, restructuring and restructuring charge.

Public (ABBV)Pharmaceutical Manufacturing10,000+ employeesabbvie.comLinkedIn

Filed: Sep 3, 2026
Filings: 8
Signals: 24

8-K · latest 10

What AbbVie's 8-K filings say

8-K
Filed Sep 3, 2026 · 3 signals
SEC EDGAR
- Acquisition completedPositive
  AbbVie completes acquisition of Apogee Therapeutics, Inc.
  The completion of this acquisition triggers significant post-merger integration (PMI) activities.
8-K
Filed Aug 18, 2026 · 3 signals
SEC EDGAR
- RestructuringNeutral
  AbbVie raises $10B in debt to fund acquisition of Apogee Therapeutics, triggering integration initiatives.
  AbbVie has secured $10 billion in financing for its acquisition of Apogee Therapeutics.
  $10B
  Total capital raised from a public notes offering to fund the acquisition of Apogee Therapeutics, Inc. and related fees.
  U.S. Bank Trust Company, National AssociationWachtell, Lipton, Rosen & Katz
8-K
Filed Aug 5, 2026 · 3 signals
SEC EDGAR
- Acquisition announcedNeutral
  AbbVie raises $9.93B in debt to fund acquisition of Apogee Therapeutics
  AbbVie is raising nearly $10 billion in net proceeds from a senior notes offering specifically to finance its acquisition of Apogee Therapeutics.
  $9.9B
  Net proceeds from debt offering to fund the acquisition of Apogee Therapeutics, Inc.
  Morgan Stanley & Co. LLCBofA Securities, Inc.J.P. Morgan Securities LLCSG Americas Securities, LLC
8-K
Filed Jul 6, 2026 · 3 signals
SEC EDGAR
- Capex increasePositive
  AbbVie invests $291M in acquired R&D and milestones in Q2 2026
  AbbVie is spending $291 million on collaborations, licensing, and asset acquisitions to strengthen its R&D pipeline.
  $291M
  Acquired IPR&D and milestones expense for Q2 2026
- Acquisition announcedNeutral
  AbbVie signals recent acquisition or licensing deal with $291M R&D expense in Q2 2026
  AbbVie incurred a $291 million expense for acquired In-Process Research & Development (IPR&D), indicating a recent asset acquisition, collaboration, or licensing agreement.
  $291M
  acquired IPR&D and milestones expense
- Margin pressureNegative
  AbbVie's Q2 2026 earnings per share to take a $0.17 hit from R&D acquisition costs
  A $291M expense for acquired R&D will reduce Q2 earnings per share by $0.17, putting pressure on short-term profitability.
8-K
Filed Jun 22, 2026 · 3 signals
SEC EDGAR
- Acquisition announcedNeutral
  AbbVie announces definitive agreement to acquire Apogee Therapeutics on June 22, 2026
  This acquisition will trigger significant post-merger integration activities, creating needs for IT system consolidation, data migration, and process harmonization across the combined entities.
8-K
Filed Apr 3, 2026 · 2 signals
SEC EDGAR
- Capex increaseNeutral
  AbbVie reports $744M expense for acquired R&D and milestones in Q1 2026, signaling major investment.
  The $744M pre-tax expense for In-Process Research & Development (IPR&D) and milestones indicates significant spending on collaborations, licensing, and asset acquisitions to bolster its drug pipeline.
  $744M
  Acquired IPR&D and milestones expense for Q1 2026
8-K
Filed Feb 26, 2026 · 3 signals
SEC EDGAR
- Debt refinancingNeutral
  AbbVie raises $7.95B in net proceeds from senior notes offering to refinance existing debt.
  AbbVie is raising capital to repay a $4.0B term loan facility maturing in May 2026 and for general corporate purposes.
  $8B
  Net proceeds from senior notes offering for debt repayment and general corporate purposes.
  J.P. Morgan Securities LLCBofA Securities, Inc.Morgan Stanley & Co. LLCWells Fargo Securities, LLC
8-K
Filed Jan 7, 2026 · 4 signals
SEC EDGAR
- Acquisition announcedNeutral
  AbbVie discloses $1.3B expense for Q4 2025 R&D acquisitions and licensing deals
  AbbVie is absorbing a $1.3 billion pre-tax expense for acquired In-Process R&D (IPR&D) and milestones, indicating significant recent investment in external innovation through acquisitions or licensing.
  $1.3B
  Acquired IPR&D and milestones expense for Q4 2025

Showing 10 of 24 filing signals. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track AbbVie with the Signal API

One POST /v1/companies/enrich call with abbvie.com returns AbbVie 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","signal_types":["sec-8k"],"limit":20}'

Same industry

Questions about AbbVie 8-K

When did AbbVie file its latest 8-K?

AbbVie filed its latest 8-K on Sep 3, 2026. The one before it was filed on Aug 18, 2026.

What did AbbVie disclose in its latest 8-K?

From the filing dated Sep 3, 2026: AbbVie completes acquisition of Apogee Therapeutics, Inc.

Where can I read AbbVie's 8-K filing?

The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/1551152/000110465926104940/tm2624674d1_8k.htm. This page summarizes what the filing says and links to it.

Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of Sep 30, 2026.

How this data is built →Get it from the Signal API →

What AbbVie's 8-K filings say: 8 filings, latest Sep 3, 2026

What AbbVie's 8-K filings say

Track AbbVie with the Signal API

8-K at related companies

Questions about AbbVie 8-K